Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 295 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
3. Cita con resumen
Anónimo. Hypertension artérielle essentielle chez un adulte: premiers traitements. Prescrire 2015;35:683-6. [Ref.ID 99722]
4. Cita con resumen
Viola E, Pittoni AC, Drahos A, Moretti U, Conforti A. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase. Drug Saf 2015;38:889-94. [Ref.ID 99615]
5. Cita con resumen
Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L, Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med 2014;371:2061-71. [Ref.ID 98365]
6.Tiene citas relacionadas
de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013;369:1960-2. [Ref.ID 96540]
7.Tiene citas relacionadas Cita con resumen
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903. [Ref.ID 96537]
8. Cita con resumen
Andrews PA. Gout. Effect of commonly prescribed drugs on incidence of gout. BMJ 2013;347:22. [Ref.ID 96433]
9. Cita con resumen
Anónimo. Drug-induced liver injury. Australian Prescriber 2013;36:168-9. [Ref.ID 96320]
10. Cita con resumen
Burton TM. Dispute flares inside FDA over safety of popular blood-pressure drugs . Wall St J 2013:30 de mayo. [Ref.ID 95523]
11. Cita con resumen
Svanström H, Pasternak B, Hvid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012;307:1506-12. [Ref.ID 92701]
13.Enlace a cita original
Desai RJ, Ashton CM, Deswal A, Morgan RO, Mehta HB, Chen H, Aparasu RR, Johnson ML. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf 2012;21:233-40. [Ref.ID 92465]
14.Tiene citas relacionadas Cita con resumen
Choi HK, Soriano LC, Zhang Y, García Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:18. [Ref.ID 92354]
15.Tiene citas relacionadas
Ruilope LM. Antihypertensive in people with gout or asymptomatic hyperuricaemia. BMJ 2012;344:9. [Ref.ID 92350]
16.Tiene citas relacionadas Cita con resumen
Hoobs FDR. Angiotensin receptor blockers and cardiovascular outcomes. BMJ 2011;342:985-6. [Ref.ID 90784]
17. Cita con resumen
The ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38. [Ref.ID 90632]
20. Cita con resumen
Anónimo. Polypillomania. Drug Ther Bull 2011;49:13. [Ref.ID 90128]
Seleccionar todas
 
 1 a 20 de 295 siguiente >>